Results 41 to 50 of about 379,801 (144)

DataSheet_1_BNT162b2 COVID-19 vaccination in children alters cytokine responses to heterologous pathogens and Toll-like receptor agonists.zip

open access: yes, 2023
BackgroundVaccines can have beneficial off-target (heterologous) effects that alter immune responses to, and protect against, unrelated infections. The heterologous effects of COVID-19 vaccines have not been investigated in children.AimTo investigate ...
Nicole L. Messina (10518191)   +9 more
core   +1 more source

Safety and immunogenicity of heterologous and homologous inactivated and adenoviral-vectored COVID-19 vaccine regimens in healthy adults: a prospective cohort study

open access: yesHuman Vaccines & Immunotherapeutics, 2022
In light of intermittent supply shortages of individual vaccines and evidence of rare but serious adverse events after vaccination, heterologous regimens for COVID-19 vaccines have gained significant interest. This study aims to assess the reactogenicity
Nasamon Wanlapakorn   +11 more
doaj   +1 more source

Neonatal BCG vaccination reduces interferon gamma responsiveness to heterologous pathogens in infants from a randomised controlled trial [PDF]

open access: yes, 2020
Background Bacille Calmette-Guérin (BCG) vaccination has beneficial non-specific (heterologous) effects that protect against non-mycobacterial infections.
Messina, NL   +35 more
core   +1 more source

Heterologous vaccine interventions: boosting immunity against future pandemics

open access: yesMolecular Medicine, 2021
While vaccines traditionally have been designed and used for protection against infection or disease caused by one specific pathogen, there are known off-target effects from vaccines that can impact infection from unrelated pathogens.
Daniela Marín-Hernández   +2 more
doaj   +1 more source

Heterologous vaccine immunogenicity, efficacy, and immune correlates of protection of a modified-live virus porcine reproductive and respiratory syndrome virus vaccine

open access: yesFrontiers in Microbiology, 2022
Although porcine reproductive and respiratory syndrome virus (PRRSV) vaccines have been available in North America for almost 30 years, many vaccines face a significant hurdle: they must provide cross-protection against the highly diverse PRRSV strains ...
Jessica Proctor   +9 more
doaj   +1 more source

Safety of heterologous ChAdOx1-S/BNT162b2 primary schedule versus homologous BNT162b2 vaccination: Insights from an Italian post-marketing study, 2021

open access: yesHuman Vaccines & Immunotherapeutics, 2023
During COVID-19 vaccination campaign, possible ChAdOx1-S-associated risks of thrombosis with thrombocytopenia syndrome led to implement ChAdOx1-S/BNT162b2 heterologous vaccination, despite the limited information on its reactogenicity and safety.
Francesca Fortunato   +6 more
doaj   +1 more source

Heterologous vaccination (ChAdOx1 and BNT162b2) induces a better immune response against the omicron variant than homologous vaccination

open access: yesJournal of Infection and Public Health, 2023
Background: The ongoing COVID-19 pandemic has seen the emergence of numerous novel variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus.
Jaeeun Yoo   +7 more
doaj   +1 more source

Heterologous Prime-boost COVID-19 Vaccination

open access: yesJK Science, 2021
There is a significant recent international interest in heterologous prime-boost COVID-19 vaccination. It may prove useful in avoiding the supply shocks or shortages that might otherwise reduce the speed of vaccine roll-out in any country including ...
Vishal R. Tandon, Annil Mahajan
doaj  

Lack of immune responses to Mycobacterium tuberculosis DosR regulon proteins following Mycobacterium bovis BCG vaccination. [PDF]

open access: yes, 2007
Mycobacterium bovis BCG is widely used as a vaccine against tuberculosis (TB), despite its variable protective efficacy. Relatively little is known about the immune response profiles following BCG vaccination in relation to protection against TB. Here we
Klein, Michèl R   +12 more
core   +1 more source

Broad anti–SARS-CoV-2 antibody immunity induced by heterologous ChAdOx1/mRNA-1273 vaccination

open access: yes, 2022
Heterologous prime-boost immunization strategies have the potential to augment COVID-19 vaccine efficacy We longitudinally profiled severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S)–specific serological and memory B cell (MBC ...
Normark, Johan   +45 more
core   +1 more source

Home - About - Disclaimer - Privacy